Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)
Telix Pharmaceuticals (TLX) reported Non-Current Assets of $833.7 million for Q4 2025, up 113.24% year-over-year from $391.0 million in Q4 2024, and up 113.24% quarter-over-quarter from $391.0 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has 3 years of Non-Current Assets data on file, last reported at $833.7 million in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $833.7 million, up 113.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $833.7 million (up 113.24% YoY), and the FY2025 annual result was $833.7 million, up 125.17% from the prior year.
- Non-Current Assets rose to $833.7 million in Q4 2025 per TLX's latest filing, from $391.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $833.7 million in Q4 2025 and troughed at $112.9 million in Q4 2023.
- A 3-year average of $445.9 million and a median of $391.0 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 246.25% in 2024, then jumped 113.24% in 2025.
- A 3-year view of Non-Current Assets shows it stood at $112.9 million in 2023, then surged by 246.25% to $391.0 million in 2024, then jumped by 113.24% to $833.7 million in 2025.
- Business Quant data shows TLX's Non-Current Assets at $833.7 million in Q4 2025, $391.0 million in Q4 2024, and $112.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 39.71 Mn |
| 10 | Telix Pharmaceuticals | 4.56 Bn | 4.42 Bn | - | 833.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 833.71 Mn |
| Dec 31, 2024 | 390.98 Mn |
| Dec 31, 2023 | 112.92 Mn |